Literature DB >> 30896532

Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Mohammad K Khan1, Tahseen H Nasti, Zachary S Buchwald, Ralph R Weichselbaum, Stephen J Kron.   

Abstract

It has long been recognized that combining radiotherapy with cytotoxic drugs such as cisplatin can improve efficacy. However, while concurrent chemoradiotherapy improves patient outcomes, it comes at costs of increased toxicity. A tremendous opportunity remains to investigate drug combinations in the clinical setting that might increase the benefits of radiation without additional toxicity. This chapter highlights opportunities to apply repurposing of drugs along with a mechanistic understanding of radiation effects on cancer and normal tissue to discover new therapy-modifying drugs and help rapidly translate them to the clinic. We survey candidate radiosensitizers that alter DNA repair, decrease hypoxia, block tumor survival signaling, modify tumor metabolism, block growth factor signaling, slow tumor invasiveness, impair angiogenesis, or stimulate antitumor immunity. Promising agents include widely used drugs such as aspirin, metformin, and statins, offering the potential to improve outcomes, decrease radiation doses, and lower costs. Many other candidate drugs are also discussed.

Entities:  

Mesh:

Year:  2019        PMID: 30896532      PMCID: PMC6518392          DOI: 10.1097/PPO.0000000000000369

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  158 in total

Review 1.  The role of DNA single- and double-strand breaks in cell killing by ionizing radiation.

Authors:  P L Olive
Journal:  Radiat Res       Date:  1998-11       Impact factor: 2.841

2.  Biomarkers for acute radiation syndrome: challenges for developing radiation countermeasures following animal rule.

Authors:  Vijay K Singh; Madison Simas; Harvey Pollard
Journal:  Expert Rev Mol Diagn       Date:  2018-10-11       Impact factor: 5.225

3.  Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Authors:  Hsu-Ping Kuo; Scott A Ezell; Karl J Schweighofer; Leo W K Cheung; Sidney Hsieh; Mutiah Apatira; Mint Sirisawad; Karl Eckert; Ssucheng J Hsu; Chun-Te Chen; Darrin M Beaupre; Matthias Versele; Betty Y Chang
Journal:  Mol Cancer Ther       Date:  2017-04-20       Impact factor: 6.261

4.  Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation.

Authors:  Virginia Wedell Osborn; Shan-Chin Chen; Joseph Weiner; David Schwartz; David Schreiber
Journal:  Tumori       Date:  2015-09-30       Impact factor: 2.098

5.  Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature.

Authors:  B Stoelcker; B Ruhland; T Hehlgans; H Bluethmann; T Luther; D N Männel
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

6.  Filgrastim improves survival in lethally irradiated nonhuman primates.

Authors:  Ann M Farese; Melanie V Cohen; Barry P Katz; Cassandra P Smith; Allison Gibbs; Daniel M Cohen; Thomas J MacVittie
Journal:  Radiat Res       Date:  2012-12-04       Impact factor: 2.841

7.  Nobel Lecture. Yeast and cancer.

Authors:  Leland H Hartwell
Journal:  Biosci Rep       Date:  2002 Jun-Aug       Impact factor: 3.840

8.  The convergence of radiation and immunogenic cell death signaling pathways.

Authors:  Encouse B Golden; Ilenia Pellicciotta; Sandra Demaria; Mary H Barcellos-Hoff; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-08-07       Impact factor: 6.244

9.  Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.

Authors:  K J Gash; A C Chambers; D E Cotton; A C Williams; M G Thomas
Journal:  Br J Cancer       Date:  2017-06-22       Impact factor: 7.640

Review 10.  ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.

Authors:  Shundong Cang; Chaitanya Iragavarapu; John Savooji; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-11-20       Impact factor: 17.388

View more
  4 in total

1.  Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity.

Authors:  Daniel A Pomeranz Krummel; Tahseen H Nasti; Milota Kaluzova; Laura Kallay; Debanjan Bhattacharya; Johannes C Melms; Benjamin Izar; Maxwell Xu; Andre Burnham; Taukir Ahmed; Guanguan Li; David Lawson; Jeanne Kowalski; Yichun Cao; Jeffrey M Switchenko; Dan Ionascu; James M Cook; Mario Medvedovic; Andrew Jenkins; Mohammad K Khan; Soma Sengupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-10-24       Impact factor: 7.038

Review 2.  Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.

Authors:  Vijay K Singh; Thomas M Seed
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

3.  Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.

Authors:  Dina V Hingorani; Jessica L Crisp; Matthew K Doan; Maria F Camargo; Maryam A Quraishi; Joseph Aguilera; Mara Gilardi; Larry A Gross; Tao Jiang; Wei T Li; Weg M Ongkeko; Ezra E W Cohen; J Silvio Gutkind; Stephen R Adams; Sunil J Advani
Journal:  Biomaterials       Date:  2020-04-11       Impact factor: 15.304

4.  Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation.

Authors:  Minhui Chen; Guanxi Qiao; Bonnie L Hylander; Hemn Mohammadpour; Xiang-Yang Wang; John R Subjeck; Anurag K Singh; Elizabeth A Repasky
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.